3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Turcot syndrome
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Gynecologic Cancers
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Surveys and Questionnaires
23
Radiotherapy
22
Letrozole
22
Doxorubicin
21
Megestrol Acetate
20
olaparib
19
lenvatinib
19
Specimen Handling
18
Taxes
17
Magnetic Resonance Spectroscopy
17
Docetaxel
17
Nivolumab
16
dostarlimab
15
Metformin
15
Blood Specimen Collection
14
Observation
13
Gemcitabine
13
Biopsy
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
temsirolimus
10
abemaciclib
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Immune Checkpoint Inhibitors
×
Gynecologic
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled